CT-388
| Identifiers | |
|---|---|
| CAS Number | |
CT-388 is a "biased" dual GLP-1 and GIP receptor agonist/modulator with minimal to no beta-arrestin coupling at either receptor and is designed to be administered as once weekly subcutaneous injection.[1] In a 24-week trial participants averaged 18.8 percent placebo adjusted weight loss. The drug is developed by Roche/Genentech.[2][3][4]
References
[edit]- ↑ Chakravarthy, Manu; ArgüElles-Tello, Federico A.; Sun, Ana Liza A.; Elliott, Michael; Acosta, Luis; Rankin, Jonathon E.; Hansen, Stig K. (20 June 2023). "75-LB: CT-388, a Novel Once-Weekly Dual GLP-1 and GIP Receptor Modulator, Is Safe, Well-Tolerated, and Produces More than 8% Weight Loss in Four Weeks in Overweight and Obese Adults". Diabetes. 72 (Supplement_1). doi:10.2337/db23-75-LB.
- ↑ "Genentech: Press Releases | Wednesday, May 15, 2024". www.gene.com.
- ↑ Constantino, Annika Kim (16 May 2024). "Roche says weight loss drug shows promising results in early trial". CNBC. Retrieved 27 May 2024.
- ↑ "Roche reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity". Roche: Press Releases. May 16, 2024. Retrieved 2024-07-26.